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Abstract: Tight junctions, or zonula occludens, are the most apical component of the junc-
tional complex and provide one form of cell–cell adhesion in epithelial and endothelial cells. 
Nearly 90% of malignant tumors are derived from the epithelium. Loss of cell–cell adhesion 
is one of the steps in the progression of cancer to metastasis. At least three main tight junction 
family proteins have been discovered: occludin, claudin, and junctional adhesion molecule 
(JAM). Claudins are the most important structural and functional components of tight junction 
integral membrane proteins, with at least 24 members in mammals. They are crucial for the 
paracellular flux of ions and small molecules. Overexpression or downregulation of claudins is 
frequently observed in epithelial-derived cancers. However, molecular mechanisms by which 
claudins affect tumorigenesis remain largely unknown. As the pivotal proteins in epithelial 
cells, altered expression and distribution of different claudins have been reported in a wide 
variety of human malignancies, including pancreatic, colonic, lung, ovarian, thyroid, prostate, 
esophageal, and breast cancers. In this review, we will give the readers an overall picture of the 
changes in claudin expression observed in various cancers and their mechanisms of regulation. 
Downregulation of claudins contributes to epithelial transformation by increasing the paracel-
lular permeability of nutrients and growth factors to cancerous cells. In the cases of upregulation 
of claudin expression, the barrier function of the cancerous epithelia changes, as they often 
display a disorganized arrangement of tight junction strands with increased permeability to 
paracellular markers. Finally, we will summarize the literature suggesting that claudins may 
become useful biomarkers for cancer detection and diagnosis as well as possible therapeutic 
targets for cancer treatment.
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Introduction to tight junctions and cell–cell 
adhesion
Cell-to-cell adhesion in epithelial cell sheets is maintained mainly through two types 
of junctions: adherens junction and tight junction. A number of studies have focused 
their attention on the transmembrane protein of the adherens junction.1,2 Only in recent 
years has the importance of tight junction proteins in epithelial cell proliferation, 
survival, apoptosis, and differentiation been recognized.
Tight junctions are involved in cell-to-cell adhesion and serve two major functions 
in epithelial cell layers: the barrier (or gate) function and the fence function. The barrier 
function of tight junctions regulates the passage of ions, water, and various macro-
molecules, even cancer cells, through paracellular spaces. Thus, the barrier function is 
relevant to edema, jaundice, diarrhea, and blood-borne metastasis. On the other hand, 
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the fence function maintains the cell polarity. In other words, 
tight junctions work as a fence to prevent the intermixing of 
molecules in the apical membrane with those in the lateral 
membrane. This fence function is highly involved in cancer 
cell biology because loss of cell polarity occurs in many types 
of cancer cells. The fence and barrier functions of the tight 
junction have a common feature of compartmentalization: 
the fence function is performed at the subcellular level and 
the barrier function is performed at the organ level. Finally, 
because of the ability of tight junction proteins to recruit sig-
naling proteins, tight junctions have also been hypothesized 
to be involved in the regulation of cell proliferation, differ-
entiation, and many other cellular functions.3,4
Introduction to claudins
Claudins were first cloned and named in 1998 by Mikio et al.5 
The name “claudin” comes from the Latin word “claudere” 
(“to close”), suggesting the barrier role of these proteins. Clau-
dins are a multigene family and encode tetraspan membrane 
proteins that are crucial structural and functional components 
of tight junctions. Claudins have important roles in regulat-
ing paracellular permeability and maintaining cell polarity in 
epithelial and endothelial cell sheets.6,7 There are currently 24 
claudin members in mammals, but claudin-13 is missing in 
humans.  Claudin members are divided into classic and non-
classic claudins based on their sequence similarity. Sequence 
similarity is determined by the alignment and phylogenetic 
tree analysis of whole-length sequences of claudins. Classic 
claudins include claudins 1–10, 14, 15, 17, and 19, and non-
classic claudins contain claudins 11–13, 16, 18, and 20–24.8 
Classic claudins exhibit a much stronger sequence homology 
than non-classic claudins. The subdivision of claudin members 
into classic and non classic groups was initially suggested from 
the sequence analysis of mouse claudin proteins. This analysis 
was subsequently extended to human claudins.7,8
In recent years, the roles of claudin proteins in human 
physiology and pathophysiology, including carcinoma devel-
opment, are just beginning to be unraveled. Several claudin 
knockout mouse models have been generated over the past 
10 years, and their diverse phenotypes clearly demonstrate 
the importance of claudin proteins in maintaining the  tissue 
integrity and homeostasis in various organs. Although 
the underlying mechanisms of claudin regulation in various 
tissues and their exact roles in normal physiology as well as 
in disease states are being elucidated, more research work 
remains to be done.9–14 In this review, we discuss the con-
ceptual framework concerning claudins and their potential 
implications in cancer. We anticipate that, in the next several 
years, our understanding of the potential role of claudins 
in the regulation of tumorigenesis will be significantly 
increased, which may, in turn, provide new approaches for 
the targeted therapy.
Role of claudins in tight junctions
Tight junctions seal the paracellular cleft of epithelia 
and endothelia and form crucial barriers between tissue 
 compartments. Tight junctions consist of integral membrane 
proteins including occludin, claudins, and tight junction-
 associated proteins, such as ZO-1. Recent studies demon-
strate the multilateral interactions between tight junction 
proteins.3,4,6 Of these molecules, claudins are responsible for 
the formation of tight junction strands and are connected to 
the actin cytoskeleton mediated by ZO-1.3,4,6
Claudins are the most important components of tight 
junctions. They form the paracellular barrier that controls 
the flux of ions and small molecules in the intercellular space 
between epithelial cells. Claudins have four transmembrane 
domains with N- and C-termini in the cytoplasm. The first 
extracellular loop consists of about 53 amino acids and the 
second one is much smaller, with about 24 amino acids. 
The N-terminal end is usually very short (four to ten amino 
acids), while the C-terminal end ranges from 21 to 63 amino 
acids and is necessary for the localization of these proteins 
in the tight junctions (see Figure 1). It is anticipated that the 
cysteines of an individual claudin can form intramolecular or 
intermolecular disulfide bonds. All human claudins (with the 
exception of claudin-12) contain a motif at the C-terminus 
that let them bind to PDZ (PSD-95/DLG/ZO-1) domains of 
scaffold proteins.15–17
Claudins are critical for sealing the epithelial sheets and 
controlling paracellular flux of ions and small molecules. 
Claudins are present in normal tissues, hyperplastic condi-
tions, benign neoplasms, and cancers that exhibit epithelial 
differentiation. Loss of claudin expression has been reported 
in several malignancies. Differential expression of various 
claudin family members in cancer can potentially be used 
to confirm the histologic identity of certain types of cancer 
and exclude others.7,9–13
The expression pattern of claudins is highly tissue-
 specific, and most tissues express multiple claudins. Claudins 
can interact with claudins from adjacent cells in a homotypic 
or heterotypic fashion to form tight junctions. Many stud-
ies suggest that the combination of claudins determines the 
selectivity and permeability of tight junctions in a given 
 tissue.6–8 Claudins can be polymerized together between 
epithelial cells to form an adhesive structure.
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Role of claudins and tight junctions 
in cancer
The function of claudins in the maintenance of normal 
epithelial cell homeostasis has been well studied; however, 
their role in the process of tumorigenesis is less clear. The 
exact biological significance of altered claudin expression 
in cancer remains largely unknown.
Cancer cells can spread from the primary site to other 
parts of the body, a process known as metastasis. Dur-
ing cancer metastasis, several important steps need to be 
undertaken. An important step in cancer progression is the 
epithelial–mesenchymal transition. During this process, 
epithelial cells downregulate cell–cell adhesion structures, 
alter their polarity, reorganize their cytoskeleton, and become 
isolated and motile.18 Tight junctions are involved in this 
cancer metastatic process. Claudin-6 decreases in breast 
invasive ductal carcinomas and is inversely correlated with 
lymph node metastasis.19 Reduced expression of claudin-7 
is correlated with higher tumor grade and locoregional and 
distant metastases, including locoregional recurrences.20 It 
has been reported that claudin-2 level is elevated in liver 
metastases. The first claudin-2 extracellular loop is essential 
for mediating tumor cell–hepatocyte interaction and the abil-
ity of breast cancer cells to form liver metastases in vivo.21 
Claudin-3 and -4 control tumor growth and metastases by 
sustaining expression of E-cadherin and limiting β-catenin 
signaling.22
The association between altered claudin expression 
and cancer has been widely reported since the discovery of 
claudins.23,24 As shown in Table 1,25–90 the level of claudin-1 
has been found to be reduced in breast cancer as well as 
in colon cancer.28,30 Claudin-7 has also been found to be 
downregulated in invasive breast cancer and in head and 
neck cancers.66,68 These reports of decreased tight junction 
protein expression in cancer are consistent with the gener-
ally accepted idea that tumorigenesis is accompanied by 
the disruption of tight junctions, a process that may play 
an important role in the loss of cohesion, invasiveness, and 
lack of differentiation observed in cancer cells. Paradoxi-
cally, other studies have shown that certain claudin proteins 
are upregulated in cancer (see Table 1).29,67 In fact, many 
published studies reported an overexpression of claudins 
in various cancers (see Table 1).35,36,56,58 For example, gene 
expression study of ovarian cancer showed that claudin-3 
and -4 were among the most highly upregulated genes in this 
cancer. Several additional reports have since confirmed the 
high expression of these two claudins in ovarian cancer. In 
addition, claudin-3 and -4 have also been reported to have an 
increased expression in other cancers, such as breast, prostate, 
and pancreatic cancers.
The loss of claudins and other tight junction proteins in 
cancer has been interpreted as a mechanism for the loss of 
cell adhesion and an important step in the progression of 
cancer to metastasis. On the other hand, as discussed previ-
ously, several claudins, including claudin-3 and -4 are often 
upregulated in many types of cancer (Table 1), suggesting that 
these proteins may have a positive effect on tumorigenesis. 
Recent research has shown that, at least in the case of ovar-
ian cells, the expression of claudin-3 and -4 may lead to an 
increase in cell invasion, motility, and survival, all of which 
are characteristics important for metastasis.91 Consistent with 
these in vitro findings is a report that claudin-4  expression 
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Figure 1 Claudin protein structure.
Notes: The claudin protein consists of four transmembrane domains and two extracellular loops (1 and 2). The N- and C-termini are located in the cytoplasm. The second 
extracellular loop has a binding site for Clostridium perfringens enterotoxin (CPe) in claudin-3 and -4. The C-terminal region contains phosphorylation sites that may be 
involved in protein–protein interactions and signal transduction.
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Table 1 Changes in claudin protein or mRNA expression in 
human tumor samples
Protein Tumor type Expression Reference
Claudin-1 Colonic  29
Squamous cell carcinoma  31
Cervical  32
Gastric  35
esophageal  36
Biliary tract  37
Keratinized (pearl)  38
Thyroid  39
Squamous cell carcinoma  
of the tongue
 40
Urothelial carcinoma  41
Hepatoblastoma  42
Squamous cell carcinoma  
of the lung
 45
Pancreatic  46
Breast  28
Colonic  30
Glioblastoma multiforme  33
Melanoma  34
Hepatocellular carcinoma  43
Adenocarcinoma of the lung  45
Claudin-2 esophageal  36
Colonic  48,49
Hepatoblastoma  51
Lung  26
Breast  47
Cervical  50
Prostate  52
Claudin-3 Gastric  35
esophageal  36
Urothelial carcinoma  41
Renal cell carcinoma  44
Breast  53
Colonic  54
Prostate  55
Ovarian  56
Pancreatic  57
Breast  47
Hepatoblastoma  51
Claudin-4 Squamous cell carcinoma  31
esophageal  36
Biliary tract  37
Squamous cell carcinoma  
of the tongue
 40
Urothelial carcinoma  41
Renal cell carcinoma  44
Breast  53
Colonic  54
Prostate  55
Ovarian  56
Gastric  58
Pancreatic  60
Thyroid  63
Lung  27
(Continued)
Table 1 (Continued)
Protein Tumor type Expression Reference
Hepatoblastoma  42
Breast  47
Gastric  59
Colonic  61
Cervical  62
Claudin-5 Adenocarcinoma of the lung  45
Pancreatic  57
Lung  27
Glioblastoma multiforme  33
Squamous cell carcinoma  
of the lung
 45
Breast  47
Claudin-6 Gastric adenocarcinoma  35
Breast (cell)  64
Claudin-7 Cervical  32
Squamous cell carcinoma  
of the tongue
 40
Urothelial carcinoma  41
Thyroid  63
Breast  67
Colonic  69,70
Gastric  73
esophageal  74
Chromophobe renal cell  
carcinoma
 76
Ovarian  78
Hepatocellular carcinoma  
(mRNA)
 79
Hepatoblastoma  42
Breast  66
Head and neck squamous  
cell carcinoma
 68
Colonic  71,72
esophageal  75
Uterus  77
Lung  25
Claudin-8 Biliary tract  37
Colonic (mRNA)  80
Claudin-9 Gastric adenocarcinoma (cell)  65
Claudin-10 Hepatocellular carcinoma  
(mRNA)
 81
Lung adenocarcinomas  82
Thyroid papillary  
(mRNA)
 83
Biliary tract  37
Claudin-11 Bladder (mRNA)  84
Claudin-12 Colonic (mRNA)  80
Claudin-16 Breast (mRNA)  90
Ovarian (mRNA)  85
Breast  86
Claudin-18 Lung adenocarcinomas  82
Pancreatic  88
Cholangiocarcinoma  88
Gastric (mRNA)  87
Claudin-23 Gastric (mRNA)  89
Abbreviation: mRNA, messenger RNA.
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in pancreatic intraductal papillary mucinous neoplasms 
was associated with a more invasive phenotype.92 Similarly, 
expression of claudin-3 and -4 was observed in advanced 
ovarian cancer but not in ovarian cystadenomas.93,94 It has 
been reported, however, that re-expression of claudin-1 in 
breast cancer cells can lead to the increased apoptosis in 
three-dimensional cultures.95 Therefore, the functions of 
claudins in cancer may be highly tissue-specific and may 
depend on the type and stage of cancer.
Several other claudin members have been reported to play 
an important role in various types of tissues; however, their 
roles in tumorigenesis are unknown. For example, CLDN13 
is a mouse-specific gene mainly expressed in tissues associ-
ated with hematopoietic function.96 Claudin-13 messenger 
RNA (mRNA) and protein are observed in colon, but they 
are undetectable in the rest of the intestines.97 Mutations in 
CLDN14 gene are known to be involved in autosomal reces-
sive deafness in humans.98 Baker et al recently reported that 
CLDN14 heterozygous mice, but not CLDN14 null mice, 
displayed several blood vessel-related phenotypes, includ-
ing abnormal distribution of basement membrane laminin 
around tumor blood vessels, increased intratumoral leakage, 
and enhanced endothelial cell proliferation.99 Patients with 
CLDN19 mutations have a high risk of progression to chronic 
renal disease.100 In human polycystic kidneys, decreased 
expression and dyslocalization of claudin-19 are noticed, 
suggesting a possible correlation between claudin-19 and 
renal disorders.101 Presently, not much is known about tis-
sue distributions or the physiological functions of claudins 
20–27. Claudin-21 and claudins 24–27 are expressed in the 
intestines, stomach, liver, and kidney.102
The mechanisms responsible for the differential expres-
sion of claudins in cancer are largely unknown; however, 
recent studies have identif ied several growth factors, 
 cytokines, and transcription factors that affect claudin 
 expression.25,103 The tumor-promoting factors, hepatocyte 
growth factor and epidermal growth factor, have been shown 
to decrease claudin-7 expression and increase claudin-1, -3, 
and -4 expressions, respectively.25,103
Critical analysis of the potential for 
targeting claudin proteins in cancer
In recent years, claudin’s potential value as a target for 
therapeutic intervention has been increasingly recognized 
regardless of its roles in tumorigenesis. This is because 
claudin proteins are expressed at the cell surface and contain 
two extracellular domains that can serve as potential target-
ing sites (Figure 1). In addition, many studies (see Table 1) 
report that some claudins are overexpressed in certain types 
of cancer while others are downregulated in different types of 
cancer, thus creating differential expression patterns between 
tumor and normal cells. Tight junction permeability is often 
higher in tumor tissues than in normal tissues, which makes 
claudins more accessible. Therefore, a therapeutic interven-
tion could be achieved.
Due to the high specificity of claudin expression patterns 
in cancer, it has been suggested that claudins may serve as 
useful molecular biomarkers for certain cancers. For example, 
claudin expression may be used as a prognostic indicator 
because low claudin-1 expression has been shown to be asso-
ciated with a poor prognosis in stage II colon  cancer.30 Clau-
din-10 expression has also been shown to be an independent 
prognostic factor for hepatocellular carcinoma recurrence 
after curative hepatectomy.81,104
It is known that claudin-3 and -4 are receptors for the 
bacterial toxin Clostridium perfringens enterotoxin (CPE). 
CPE is a single polypeptide of 35 kDa. Upon binding to its 
receptors, CPE induces cytolysis through its effects on mem-
brane permeability. The high expression levels of claudin-3 
and -4 in multiple types of cancer may provide a unique 
opportunity for anticancer therapy using CPE.  Prostate 
adenocarcinoma cells expressing claudin-3 and -4 have been 
shown to be sensitive to CPE-mediated cytolysis.55,105,106 
This CPE-mediated cytolysis was specific because prostate 
cancer cells lacking claudin-3 and -4 were unaffected by 
CPE treatment.  Similar experiments have also shown that 
breast, ovarian, and pancreatic cancer cells were sensitive to 
CPE treatment as long as these cancer cells were express-
ing claudin-3 and/or -4.53,105,107 The challenge, however, 
is that claudin-3 and/or -4 are also expressed in several 
normal human tissues, including gut, lungs, and kidneys. 
This could hinder the use of CPE for potential anti-cancer 
therapy. Therefore, whether this approach will be useful in 
the clinical setting remains to be seen.
To overcome this hurdle, it has been suggested that a 
nontoxic C-terminal CPE fragment could be delivered locally 
to normal tissues and prevent CPE toxicity during cancer 
treatment. Other potential problems with the use of CPE 
in cancer treatment include the possible immune response 
against CPE in patients receiving the treatment, the level of 
surface claudin expression, and the penetration of CPE into 
the tumor mass.53,55,105–107 Therefore, additional studies are 
required to solve these issues before CPE can be used as a 
therapeutic approach.
A study has shown that claudin peptides can be internal-
ized by specific and nonspecific pathways.108 The cellular 
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uptake of the claudin-1 peptide follows the clathrin-mediated 
endocytosis as indicated by inhibitors and respective trac-
ers for colocalization. In addition, macropinocytosis and 
caveolae-mediated endocytosis of the peptide have also been 
observed. In contrast, the claudin-5 peptide is mainly inter-
nalized via the caveolae-mediated endocytosis as evidenced 
by the colocalization with respective tracers and vesicle 
markers, whereas the nonselective macropinocytosis seems 
to be involved in a less effective manner.108
Since claudins are transmembrane proteins and contain 
two extracellular loops, they may also offer promising tar-
gets for antibody-based therapy. Antibodies that recognize 
different claudins’ extracellular loops have been produced 
and shown to specifically bind to claudins on the surface 
of the cell, providing a proof of principle for this approach. 
Besides antibody-based treatment, many small molecules 
or compounds can affect tight junction functions and, there-
fore, could potentially be used for anticancer therapy.109 For 
example, it has been reported that hydroxycamptothecin-
loaded Fe
3
O
4
 nanoparticles induce human HCC827 lung 
cancer cell apoptosis and disrupt tight junctions by internal-
izing claudin-1, -3, -4, and -7 proteins and decreasing their 
protein expressions.110 HangAmDan-B, an anti-invasive agent 
extracted from eight Korean medical animals and plants, can 
inhibit the cell migration and invasion of NCI-H460 lung 
cancer cells and tighten the tight junctions through down-
regulating claudin-1, -2, -3, and -4 at both transcriptional 
and translational levels.111 Butyrate improves the barrier 
function of intestinal epithelia and has the potential to treat 
inflammatory bowel disease. It restores the tight junctions in 
inflammatory bowel disease patients by downregulating the 
expression of claudin-1 and -2 and upregulating occludin, 
cingulin, ZO-1, and ZO-2.112
It has been suggested from the gene expression studies 
of breast and ovarian cancers56,67 that the identification of 
specific expression patterns of claudin family members could 
be used as potential biomarkers for these cancers. A cancer 
biomarker refers to a substance or process that is indicative 
of the presence of cancer in the body. Not all of the claudins 
in Table 1 are considered as biomarkers. Up until now, only 
certain claudins could be an indicative marker for diagnosis 
and disease progression. For example, claudin-7 may serve 
as an immunohistochemical biomarker in the differential 
diagnosis of chromophobe renal cell carcinoma and onco-
cytoma; claudin-4 could serve as an immunohistochemical 
biomarker in the differential diagnosis of undifferentiated 
pancreatic cancers and highly invasive pancreatic cancers; 
and the expression of claudin-10 in hepatocellular carcinomas 
can potentially serve to predict disease recurrence after cura-
tive hepatectomy.60,76,81 These findings are important because 
changes in expression patterns of claudins allow for detection, 
diagnosis, and potential treatment of drug-resistant cancers. 
Clinical trials are certainly required to establish this potential, 
but research studies on claudin functions and regulations as 
well as their roles in cancer are critically needed for provid-
ing important insight in relation to normal and neoplastic 
cellular physiology.
The fact that the expression levels of many claudin 
family members are altered in various types of cancers and 
that claudins are localized at the cell surface make claudins 
potentially attractive molecular targets for cancer therapy. 
The clinical application of using claudin-targeted therapy, 
however, will present several challenges. The most impor-
tant challenge is the systemic toxicity. Because claudins 
are expressed in the epithelia of most organs in the body, 
the toxicity issue must be addressed. The small molecules 
or synthetic compounds designed to disrupt tight junctions 
may also be a double-edged sword, because an increase in 
tight junction permeability can enhance the uptake of anti-
cancer agents, but, at the same time, it may also increase the 
nutritional uptake to promote tumor progression. Therefore, 
further studies, especially at the animal level, are needed to 
determine the toxicity issue of claudin-targeted therapy and 
to evaluate whether this approach can be applied safely and 
practically in a clinical setting.
Claudins play an indispensable role in tissue homeosta-
sis and barrier formation; our knowledge about the role of 
claudin proteins in cancer biology is, however, still limited. 
Nevertheless, with our increasing understanding of specific 
functions of claudins in various cancers, claudins may serve 
as promising tumor biomarkers as well as therapeutic targets 
in the near future.
Conclusion
Claudins are the main structural and functional proteins of 
tight junctions in epithelial cells and maintain the tissue 
homeostasis through regulating epithelial barriers, paracel-
lular transport, and signal transduction. Numerous studies 
have demonstrated the altered expression patterns of differ-
ent claudin members in a variety of diseases, particularly 
in cancers. Identifying the specific functions of claudins in 
tumorigenesis has become one of the main research focuses 
in the field of cell biology. It is still unclear what the associa-
tion between altered claudin expression and tumorigenesis is, 
despite great research efforts in the last decade. With rapid 
research advancement and newly developed technology, 
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however, the role of claudins in cancer and its clinical 
applications in cancer detection, diagnosis, and potential 
therapeutic intervention may become a valid approach in 
the near future.
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